SynthesisStem cells translational medicine2026
Therapeutic potential of MSCs and their exosomes in hepatic Ischaemia-Reperfusion injury: a systematic review and meta-analysis of rodent studies.
Synthesis in Stem cells translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveThis meta-analysis comprehensively evaluates the therapeutic efficacy and mechanisms of mesenchymal stem cells (MSCs) and their exosomes in rodent models of hepatic ischemia-reperfusion injury (HIRI), providing preclinical support for future clinical translation.
methodsIn accordance with the PRISMA guidelines, we systematically searched PubMed, Web of Science, Embase, Cochrane Library, and ClinicalTrials.gov for studies published from inception to January 13, 2025, and identified 64 eligible studies. Risk of bias was evaluated using the SYRCLE tool, and Review Manager 5.4.1 was employed for meta-analysis, calculating SMD and 95%CI. Primary outcomes included liver function (ALT/AST), histopathological scores (Suzuki's score, necrotic area ratio), inflammatory cytokines (TNF-α), and apoptosis markers (c-caspase 3).
resultsMSCs and their exosomes significantly ameliorated HIRI. In the 60-minute ischemia group, ALT (SMD = 3.49, P < .00001) and AST (SMD = 3.86, P < .00001) decreased, along with lower Suzuki scores (SMD = 3.12), necrotic area ratios (SMD = 3.56), and TNF-α levels (SMD = 2.83). In the 90-minute group, ALT (SMD = 4.09, P < .00001) and AST (SMD = 3.78, P < .00001) were also reduced. Mechanistically, MSCs exert therapeutic effects through antioxidative, anti-inflammatory, anti-apoptotic, and pro-regenerative pathways. Considerable heterogeneity (I2 = 52-86%) was observed, likely due to variations in dosage (1 × 105-1 × 109 cells), administration routes (intravenous/portal vein), and reperfusion durations (3-24 hours). Genetic modifications (e.g., HO-1 overexpression) further enhanced therapeutic outcomes.
conclusionMSCs and their exosomes mitigate HIRI through multi-target mechanisms but requires standardized protocols. Future studies should prioritize large-animal validation and translational research to facilitate precision clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.